Company intelligence / Profile preview
Flamingo Therapeutics
Leuven, Flemish Brabant, Belgiumflamingotx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Flamingo Therapeutics has advanced its lead antisense oligonucleotide danvatirsen into a randomized international Phase II trial in combination with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma. Early results show clinical activity. A separate investigator-led Phase I study evaluates danvatirsen as monotherapy and with venetoclax in relapsed/refractory AML/MDS. The company’s second asset, FLM‑7523 targeting MALAT1 lncRNA, is IND-ready to enter first-in-human studies targeting solid tumors.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antisense oligonucleotides (ASOs)RNA-targeted therapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Merck & Co., Inc. – using pembrolizumab/KEYTRUDA® as combination partner in clinical trials.Ionis Pharmaceuticals – original discoverer of danvatirsen licensed to Flamingo.Academic partnerships with Montifore Einstein Comprehensive Cancer Center and MD Anderson Cancer Center on investigator-led trials.
Beyond the preview
Go deeper on Flamingo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flamingo Therapeutics.